Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2011-09-05
2012-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ACTIONS - Aortic Counterpulsation to Improve Outcomes in Noncardiac Surgery
NCT01253356
Ischaemia-réperfusion During the Coronary Surgery With Beating Heart
NCT01771978
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
NCT00082121
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
NCT00316212
Study Of Factors Favoring The Onset Of Novo Atrial Fibrillation In The Immediate Aftermath Of Coronary Artery Bypass Surgery
NCT02042547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ropivacaine
Conventional PCA morphine +TAP-block ropivacaine 0.2%
Ropivacaine
TAP-block Ropivacaine 0.2% during 48 hours
TAP-block with placebo
Conventional PCA morphine treatment with TAP-block with placebo
Placebo
TAP-block with placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacaine
TAP-block Ropivacaine 0.2% during 48 hours
Placebo
TAP-block with placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person who has given his written consent
Exclusion Criteria
* Patient with infection
* Use of opioids in the long term
* History of chronic pain
* Higher functions incompatible with the functioning of the PCA
* Patients under guardianship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric STEINMETZ
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claude GIRARD, Professor
Role: PRINCIPAL_INVESTIGATOR
Anesthesia unit
Eric STEINMETZ, Professor
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular and thoracic surgery unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiovascular and thoracic surgery unit, CHU Dijon
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002355-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.